Glycosylation of NT-proBNP: What clinicians and laboratories need to know

NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most significant is glycosylation of NT-proBNP, which can interfere with antibody binding in current assays and lead to systematic underestimation of NT-proBNP concentrations, potentially leading to false diagnoses and suboptimal clinical care.

This webinar brings together leading experts to connect clinical practice with emerging insights into NT-proBNP biology and assay performance.

Prof. Peder Myhre will present "NT-proBNP in clinical practice: Current use and unresolved challenges" reviewing the role of NT-proBNP in diagnosis and management of heart failure, while highlighting limitations and unmet needs in real-world practice.

Prof. Robert Christenson will follow with "NT-proBNP Glycosylation: Biology and implications on assay performance" focusing on the molecular basis of NT-proBNP glycosylation, its impact on epitope recognition, and the consequences for assay design, analytical variability, and result comparability across platforms.

Together, these perspectives will deepen understanding of how NT-proBNP biology intersects with laboratory measurement and clinical interpretation. Advances toward glycosylation-independent NT-proBNP testing may support improved diagnostic accuracy, affordability and accessibility. Attendees will gain insight into how glycosylation can affect diagnostic reliability and patient management.

Gentian’s ongoing development of open channel clinical chemistry glycosylation-independent NT-proBNP assay represents an important step toward more reliable heart failure diagnostics. Ongoing studies aim to clarify the impact of glycosylation and demonstrate improved diagnostic performance while enabling broader access via open clinical chemistry platforms.

Learning Objectives:

• Current clinical role of NT-proBNP in heart failure diagnosis and management.

• Current strengths and unresolved challenges of NT-proBNP in heart failure assessment and how they affect clinical decision-making.

• Glycosylation as systematic source of analytical and clinical uncertainty.

• The impact of NT-proBNP glycosylation on assay performance and implications for interpretation.